Alaaeldin et al. [56] demonstrated that Azilsartan inhibited the NF-kB/IL-6/JAK2/STAT3 signaling pathway and inhibited the EMT expression in breast cancer cells. The gene discussed is STAT3; the disease is breast cancer.